Comparative efficacy and safety of sacituzumab govitecan versus chemotherapy in metastatic breast cancer: An updated meta-analysis and systematic review.

作者：Mehmoona Zahid, MA Ali, Muhammad Atif Mazhar, Eshal Atif, Muhammad Hassan Ashraf Rai, Sadia Qazi, Shabih Raza Farista, Vishan Das, Hira Naz, Sidra Naz · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco.2026.44.19_suppl.30 · 研究领域：HER2/EGFR in Cancer Research、Advanced Breast Cancer Therapies、Cancer Immunotherapy and Biomarkers

30 Background: Sacituzumab Govitecan (SG) is a Trop-2–directed antibody–drug conjugate with demonstrated survival benefit in metastatic breast cancer. Estimating the magnitude of that benefit has been complicated by differences in trial populations, chemotherapy comparators, and the accumulation of new trial data. We performed an updated meta-analysis to pool estimates of PFS, OS, tumor response, and key adverse events across available comparative trials. Methods: We conducted a systematic review and meta-analysis per PRISMA guidelines, searching PubMed, Embase, Scopus, and the Cochrane Library from inception to 29 January 2026 for comparative trials of SG versus chemotherapy in metastatic breast cancer. Two reviewers independently screened studies and extracted data; disagreements were resolved by consensus. Hazard ratios (HRs) were pooled for PFS and OS; risk ratios (RRs) were used for dichotomous outcomes. Random-effects models were used as the primary analytic approach. Heterogeneity was assessed with I² and τ². Results: 4 studies (ASCENT [Bardia], TROPICS-02, Cortes 2025, Xu 2024) comprising 1,961 participants (984 SG, 977 control) were included. PFS, reported in three studies (ASCENT [Bardia], Cortes 2025, Xu 2024), favored SG (HR 0.54; 95% CI 0.43–0.69; I²=70.3%). OS, reported in three studies (ASCENT [Bardia], TROPICS-02, Xu 2024), was also improved (HR 0.64; 95% CI 0.49–0.83; I²=78.0%). Stable disease was significantly higher with SG across all four studies (RR 1.22;...